Menu
Search
|

Menu

Close
X

Otonomy Inc OTIC.OQ (NASDAQ Stock Exchange Global Select Market)

2.60 USD
+0.01 (+0.39%)
As of Oct 19
chart
Previous Close 2.59
Open 2.56
Volume 2,831
3m Avg Volume 52,236
Today’s High 2.66
Today’s Low 2.56
52 Week High 6.40
52 Week Low 2.21
Shares Outstanding (mil) 30.63
Market Capitalization (mil) 84.23
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
1
FY16
1
FY15
0
EPS (USD)
FY18
-0.817
FY17
-2.975
FY16
-3.691
FY15
-2.553
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
86.30
6.55
Price to Book (MRQ)
vs sector
0.84
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
0.00
14.15
LT Debt to Equity (MRQ)
vs sector
0.00
11.31
Return on Investment (TTM)
vs sector
-50.86
12.83
Return on Equity (TTM)
vs sector
-51.89
14.95

EXECUTIVE LEADERSHIP

Jay Lichter
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
David Weber
President, Chief Executive Officer, Director, Since
Salary: $530,000.00
Bonus: $127,200.00
Paul Cayer
Chief Financial and Business Officer, Since 2015
Salary: $383,675.00
Bonus: $61,388.00
Robert Savel
Chief Technical Officer, Since 2014
Salary: --
Bonus: --
Kathie Bishop
Chief Scientific Officer, Since 2017
Salary: $321,458.00
Bonus: $102,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4796 Executive Dr
SAN DIEGO   CA   92121-3090

Phone: +1619.3232200

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.

SPONSORED STORIES